Dr. David Fajgenbaum

Maybe we can find something else for angiosarcoma.

And that's when we came across a study that had been published.

I'm so annoying to them.

They're like, they're looking at me and they're like, your uncle has a terminal illness.

The last thing he needs is for his nephew to tell him or me that there's a treatment out there that can help him.

Like, that's not what he needs right now is what they're thinking.

And in my mind, I'm like, are you kidding me?

He's still here.

He's still breathing.

I just walked past a CVS.

And last time I checked, there's 4,000 drugs in that CVS.

And I know those 4,000 drugs haven't been tried for him.

So until we tried all 4,000 drugs, you can't tell me there isn't a drug in there that can help him.

And so we find a study that had been published three years earlier that basically says that four out of five people with my uncle's cancer have very high expression of something called PD-L1.

I'm here saying like, let's test this tumor for PD-L1.

And the doctor says, I'm not going to test it because no one with angiosarcoma has ever been given a PD-1 inhibitor.

I think there's like a...

less than 10% chance that this gene panel that you want to order for Michael is going to come out with anything helpful.

And I hear less than 10%.

And I'm like, that's great.